223 related articles for article (PubMed ID: 17922895)
1. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
Brearley C; Priestley A; Leighton-Scott J; Christen M
BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe.
Agersø H; Møller-Pedersen J; Cappi S; Thomann P; Jesussek B; Senderovitz T
J Clin Pharmacol; 2002 Nov; 42(11):1262-8. PubMed ID: 12412826
[TBL] [Abstract][Full Text] [Related]
3. Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.
Brimhall DB; Petri N; D'Angelo P
Clin Ther; 2018 May; 40(5):741-751. PubMed ID: 29699852
[TBL] [Abstract][Full Text] [Related]
4. Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle.
Dörr HG; Zabransky S; Keller E; Otten BJ; Partsch CJ; Nyman L; Gillespie BK; Lester NR; Wilson AM; Hyrén C; van Kuijck MA; Schuld P; Schoenfeld SL
J Pediatr Endocrinol Metab; 2003 Mar; 16(3):383-92. PubMed ID: 12705363
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe.
Voortman G; van de Post J; Schoemaker RC; van Gerven JM
Hum Reprod; 1999 Jul; 14(7):1698-702. PubMed ID: 10402370
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone therapy with a new delivery system.
Jørgensen JT; Susgaard S
Indian J Pediatr; 1991; 58 Suppl 1():43-50. PubMed ID: 1824374
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.
Liedert B; Forssmann U; Wolna P; Golob M; Kovar A
BMC Clin Pharmacol; 2010 Oct; 10():14. PubMed ID: 20961422
[TBL] [Abstract][Full Text] [Related]
8. Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system.
Bienvenu B; Aouba A; Gottenberg JE; Verstuyft C
Curr Med Res Opin; 2017 Apr; 33(4):605-611. PubMed ID: 27874307
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
True AL; Chiu YY; Demasi RA; Stout R; Patel I
Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution.
Jacobsen LV; Rolan P; Christensen MS; Knudsen KM; Rasmussen MH
Growth Horm IGF Res; 2000 Apr; 10(2):93-8. PubMed ID: 10931747
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency.
Houdijk EC; Herdes E; Delemarre-Van de Waal HA
Acta Paediatr; 1997 Dec; 86(12):1301-7. PubMed ID: 9475305
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of midazolam: a comparison of the Bioject jet injector with the conventional syringe and needle.
Bennett J; Nichols F; Rosenblum M; Condry J
J Oral Maxillofac Surg; 1998 Nov; 56(11):1249-54. PubMed ID: 9820211
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.
Lewis AL; Jordan F; Patel T; Jeffery K; King G; Savage M; Shalet S; Illum L
J Clin Endocrinol Metab; 2015 Nov; 100(11):4364-71. PubMed ID: 26425883
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of recombinant human growth hormone in different concentrations and formulations.
Vahl N; Jensen SB; Rasmussen MH; Susgaard S; Jørgensen JO; Christiansen JS; Rasmussen UF; Hilsted J
Pharmacol Toxicol; 1996 Sep; 79(3):144-9. PubMed ID: 8884873
[TBL] [Abstract][Full Text] [Related]
16. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth.
Desrosiers P; O'Brien F; Blethen S
Pediatr Endocrinol Rev; 2005 Feb; 2 Suppl 3():327-31. PubMed ID: 16456500
[TBL] [Abstract][Full Text] [Related]
17. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.
Maggio MC; Vergara B; Porcelli P; Corsello G
Ital J Pediatr; 2018 Sep; 44(1):113. PubMed ID: 30261918
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
[TBL] [Abstract][Full Text] [Related]
19. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy.
Verrips GH; Hirasing RA; Fekkes M; Vogels T; Verloove-Vanhorick SP; Delemarre-Van de Waal HA
Acta Paediatr; 1998 Feb; 87(2):154-8. PubMed ID: 9512200
[TBL] [Abstract][Full Text] [Related]
20. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
